Fundraising Fox

Cellanome

Foster City, US · Founded 2020 · Delaware corporation · 3 known investors

cellanome.com ↗

Cellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.

AI & Machine LearningBiotechData & InfrastructureDeep TechMedical Devicesin /cellanome@cellanome

Founders & leadership

MRMostafa Ronaghi
Mostafa RonaghiCofounder, Executive Board Member
OOOmead Ostadan
Omead OstadanCEO, Board Member
KO
Kazutaka OhnoExecutive Officer
AA
Ali AgahExecutive Officer, Director
TK
Tarun Kumar KhuranaExecutive Officer, Director
SP
Sandesh PatnamDirector
RCRowan Chapman
Rowan ChapmanDirector
JFJay Flatley
Jay FlatleyDirector
MK
Mehdi KhodadadSecretary

Investors · 3

8VCAustin · $100K – $50M
DCVC (Data Collective)Palo Alto · $5M – $25M
SV AngelSan Francisco

Competitors · 10

by search overlap
Diabetes Prevention Program33 shared keywords
Alterome31 shared keywordsAlterome is a clinical-stage precision oncology company developing small molecule therapies targeting mutant KRAS and AKT E17K in cancers including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancer.
Immunome30 shared keywords
Noveome Biotherapeutics23 shared keywords
Myome22 shared keywords
Freenome20 shared keywordsFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
ResearchGate17 shared keywords
Dervan et al15 shared keywords
Sensome14 shared keywords
Hallmarks of Aging: An Expanding Universe13 shared keywords

Companies competing with Cellanome for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
▶$75.9MraisedJun 2026 · 22 investors · Biotechnology
Rule 506(b)
Cellanome has filed a notice of an exempt offering of securities to raise $75,930,476.00 in New Funding. - intelligence360intelligence360.news · Jul 2026
Officers, directors & promoters on the filing
  • Mehdi KhodadadExecutive Officer
  • Mostafa RonaghiDirector
  • Sandesh PatnamDirector
  • Omead OstadanExecutive Officer, Director
  • Rowan ChapmanDirector
  • Jay FlatleyDirector
Offering amount
$75.9M
Amount sold
$75.9M
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$150MraisedJan 2024 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mehdi KhodadadExecutive Officer
  • Ali AgahExecutive Officer
  • Tarun KhuranaExecutive Officer
  • Sue McGrathExecutive Officer
  • Jay FlatleyDirector
  • Rowan ChapmanDirector
  • Mostafa RonaghiDirector
  • Omead OstadanExecutive Officer, Director, Promoter
Offering amount
$150M
Amount sold
$150M
Minimum investment
$60K
First sale
Dec 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40.7MraisedMar 2023 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Omead OstadanExecutive Officer, Director, Promoter
  • Jay FlatleyDirector
  • Kazutaka OhnoExecutive Officer
  • Mostafa RonaghiDirector
  • Rowan ChapmanDirector
Offering amount
$40.7M
Amount sold
$40.7M
First sale
Jul 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21MraisedDec 2021 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kazutaka OhnoExecutive Officer
  • Ali AgahExecutive Officer, Director
  • Mostafa RonaghiDirector
  • Tarun Kumar KhuranaExecutive Officer, Director
  • Omead OstadanDirector
Offering amount
$21M
Amount sold
$21M
First sale
Nov 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedOct 2021 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kazutaka OhnoExecutive Officer
  • Mostafa RonaghiDirector
  • Omead OstadanDirector
  • Ali AgahExecutive Officer, Director
  • Tarun Kumar KhuranaExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Sep 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news